We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Insmed

News List

Insmed Initiates ARIKAYCE Trial for MAC Lung Disease americanpharmaceuticalreview
January 11, 2021
Insmed announced the first patient was dosed in the frontline clinical trial program of ARIKAYCE® (amikacin liposome inhalation suspension) in patients with nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC).
Insmed Receives FDA Breakthrough Therapy Designation for Non-Cystic Fibrosis Bronchiectasis Treatment americanpharmaceuticalreview
June 17, 2020
Insmed announced the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation for brensocatib (formerly known as INS1007) for the treatment of adult patients with non-cystic fibrosis bronchiectasis (NCFBE) for reducing ...
Insmed Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update firstwordpharma
February 24, 2019
Insmed Incorporated a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2018 and provided a business u
Insmed appoints Leo Lee to its Board of Directors biospectrumasia
May 21, 2018
Lee has more than 21 years of experience in the pharmaceutical industry in Japan.